CYTK Cytokinetics Incorporated

14.30
+0.10  (1%)
Previous Close 14.20
Open 14.15
Price To book 4.39
Market Cap 767434682
Shares 53,666,761
Volume 430,376
Short Ratio 5.44
Av. Daily Volume 446,024

SEC filingsSee all SEC filings

  1. 8-K - Current report 171092521
  2. CT ORDER - Confidential treatment order 171063608
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171008754
  4. 8-K - Current report 17999831
  5. 8-K - Current report 17998365

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 start of trial announced July 27, 2017.
CK-2127107 - FORTITUDE-ALS
Amyotrophic lateral sclerosis (ALS)
Phase 1b trial initiation announced June 29, 2017.
CK-2127107
Limited mobility
Phase 2 initiated January 2016. Baseline data from first cohort released June 5, 2017. Cohort 2 enrollment to be completed in 2017. Data due 1Q 2018.
CK-2127107
Spinal muscular atrophy (SMA)
Phase 3 commencement announced December 1, 2016. Enrollment to continue throughout 2017.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Phase 3 data are due 4Q 2017.
Tirasemtiv - VITALITY
Amyotrophic lateral sclerosis (ALS)
Phase 2 initiated June 2016. Enrollment to continue in 2017.
CK-2127107
Chronic obstructive pulmonary disease (COPD)

Latest News

  1. Cytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
  2. Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific Meeting
  3. Options Traders Expect Huge Moves in Cytokinetics (CYTK) Stock
  4. Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the HFSA 21st Annual Scientific Meeting
  5. ETFs with exposure to Cytokinetics, Inc. : September 7, 2017
  6. Cytokinetics to Present at September Investor Conferences
  7. Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : August 29, 2017
  8. ETFs with exposure to Cytokinetics, Inc. : August 21, 2017
  9. Edited Transcript of CYTK earnings conference call or presentation 2-Aug-17 8:30pm GMT
  10. Cytokinetics, Inc. :CYTK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017
  11. Cytokinetics, Inc. breached its 50 day moving average in a Bearish Manner : CYTK-US : August 4, 2017
  12. Featured Company News - Cytokinetics Announces Positive Results for Phase-2 Clinical Trial of Omecamtiv Mecabril in Japanese Patients with Heart Failure
  13. Cytokinetics reports 2Q loss
  14. Cytokinetics, Inc. Reports Second Quarter 2017 Financial Results
  15. Investor Network: Cytokinetics, Incorporated to Host Earnings Call
  16. Cytokinetics Announces Positive Results From Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Patients With Heart Failure
  17. Cytokinetics, Inc. – Value Analysis (NASDAQ:CYTK) : July 31, 2017
  18. Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis
  19. Cytokinetics to Announce Second Quarter Results on August 2, 2017
  20. Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : July 17, 2017

SEC Filings

  1. 8-K - Current report 171092521
  2. CT ORDER - Confidential treatment order 171063608
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171008754
  4. 8-K - Current report 17999831
  5. 8-K - Current report 17998365
  6. 8-K - Current report 17984470
  7. 8-K - Current report 17946149
  8. 8-K - Current report 17938667
  9. 8-K - Current report 17936765
  10. 8-K - Current report 17858489